IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

Maria Cristina Pirosa; Marianna Sassone; Barbara Kiesewetter; Armando Lopez Guillermo; Liliana Devizzi; Eva Domingo Domènech; Alessandra Tucci; Donato Mannina; Michele Merli; Antonio Salar; Carlo Visco; Fabiana Esposito; Luisella Bonomini; Emanuele Zucca; Andrés J M Ferreri; Markus Raderer

doi:10.3324/haematol.2022.281963

IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

Haematologica. 2023 Jun 1;108(6):1671-1675. doi: 10.3324/haematol.2022.281963.

Authors

Maria Cristina Pirosa¹, Marianna Sassone², Barbara Kiesewetter³, Armando Lopez Guillermo⁴, Liliana Devizzi⁵, Eva Domingo Domènech⁶, Alessandra Tucci⁷, Donato Mannina⁸, Michele Merli⁹, Antonio Salar¹⁰, Carlo Visco¹¹, Fabiana Esposito¹², Luisella Bonomini¹³, Emanuele Zucca¹⁴, Andrés J M Ferreri², Markus Raderer³

Affiliations

¹ Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona. maria.pirosa@eoc.ch.
² Lymphoma Unit,Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan.
³ Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna.
⁴ Department of Hematology, Hospital Clínic de Barcelona, Barcelona.
⁵ Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan.
⁶ Department of Hematology, Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, Barcelona.
⁷ Division of Hematology, AO Spedali Civili di Brescia, Brescia.
⁸ Hematology Unit, AO Papardo, Messina.
⁹ Department of Haematology Ospedale di Circolo di Varese, Varese.
¹⁰ Department of Clinical Hematology Hospital del Mar, Barcelona.
¹¹ Department of Medicine, Section of Hematology, University of Verona, Verona.
¹² Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona.
¹³ Institute of Oncology Research, Bellinzona.
¹⁴ Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona.

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Clarithromycin* / therapeutic use
Humans
Lenalidomide / therapeutic use
Lymphoma, B-Cell, Marginal Zone* / drug therapy
Lymphoma, B-Cell, Marginal Zone* / pathology
Treatment Outcome

Substances

Lenalidomide
Clarithromycin

Associated data

ClinicalTrials.gov/NCT03031483
EudraCT/2015-003168-35

Grants and funding

Funding: The IELSG is supported by the Swiss Cancer Research foundation and the Swiss Cancer League. The IELSG40/CLEO academic trial was sponsored by the IELSG and was funded in part by an unrestricted research grant from Celgene.